|Articles|July 1, 2001
- Pharmaceutical Executive-07-01-2001
- Volume 0
- Issue 0
Overruled: No More Dual Pricing
Author(s)Kevin Gopal
European Union-The European Commission’s ban on GlaxoSmith–Kline’s dual pricing policy in Spain halts one of Big Pharma’s attempts to prevent parallel imports in Europe.
Advertisement
Articles in this issue
about 25 years ago
Pharmacies: OTC Price Warsabout 25 years ago
One Disease at a Timeabout 25 years ago
Overview of the Industry: A World of Opportunitiesabout 25 years ago
The Power Shiftabout 25 years ago
A Giant Stumblesabout 25 years ago
Submergedabout 25 years ago
Generic ThreatAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report
2
M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel
3
Study Shows Link Between Zepbound and Lower Healthcare Costs in Adults Aged 55 and Up with Obesity: Report
4
Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals
5